August 28, 2024
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics
FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.
Genentech Announces 93 Layoffs in California Amid Restructuring Efforts
Genentech layoffs, California job cuts, biotech industry, cancer immunology research, restructuring efforts
Cleveland Diagnostics Launches Second Annual Prostate Cancer Awareness Campaign
prostate cancer, IsoPSA test, Cleveland Diagnostics, awareness campaign, early detection
Genentech Announces 93 Layoffs in California Following Closure of Cancer Immunology Research Unit
Genentech, layoffs, California, cancer immunology research unit, biotech, workforce reduction
FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate
Invivyd, COVID-19, Pemgarda, Emergency Use Authorization, FDA, Immunocompromised, Variants
Pfizer Unveils PfizerForAll, a Direct-to-Consumer Platform for Migraine, Flu, and COVID-19 Products
PfizerForAll, Direct-to-Consumer, Migraine, Flu, COVID-19, Telehealth, Prescription Services, Vaccination Scheduling, Savings Programs
Eli Lilly Launches Direct-to-Consumer Sales of Zepbound for Weight Loss
Eli Lilly, Zepbound, weight loss medication, direct-to-consumer sales, affordable pricing, obesity treatment
Pfizer Launches PfizerForAll: A Digital Platform to Simplify Healthcare Access
PfizerForAll, digital healthcare platform, telehealth, COVID-19, flu, migraines, healthcare access, patient support services
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment